Non-interventional surveillance study of adverse events in patients with epilepsy

Acta Neurologica Scandinavica

Volumn 124, Issue 1, 2011, Pages 13-21

  Cramer, J A ^a   Steinborn, B ^b   Striano, P ^c   Hlinkova, L ^d   Bergmann, A ^e   Bacos, I ^f   Baukens, C ^g   Buyle, S ^g  

^a YALE UNIVERSITY   (United States)

^b POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^c UNIVERSITY OF GENOA   (Italy)

^d Neurologicka Ambulance   (Czech Republic)

^e Neurologie ^*  (Germany)

^f Spitalul de Neuropsihiatrie Infantila   (Romania)

^g UCB PHARMA   (Belgium)

Author keywords

Antiepileptic drugs; Lamotrigine; Levetiracetam; Monotherapy; Polytherapy; Tolerability

Indexed keywords

CLOBAZAM; CLONAZEPAM; ETIRACETAM; GABAPENTIN; LAMOTRIGINE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PREGABALIN; TIAGABINE; TOPIRAMATE; VALPROIC ACID; ZONISAMIDE;

ADOLESCENT; ADULT; ANTICONVULSANT THERAPY; APPETITE; ARTHRALGIA; ARTICLE; CLINICAL TRIAL; COGNITIVE DEFECT; CROSS-SECTIONAL STUDY; DIPLOPIA; DIZZINESS; DRUG EFFICACY; DRUG INDUCED HEADACHE; DYSARTHRIA; EPILEPSY; FEMALE; GAIT DISORDER; GASTROINTESTINAL DISEASE; HAIR; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MONOTHERAPY; MULTICENTER STUDY; OBSERVATIONAL STUDY; PHYSICIAN; QUESTIONNAIRE; SEDATION; SEIZURE; SIDE EFFECT; SKIN MANIFESTATION; TOOTH DISEASE; TREMOR; WEIGHT GAIN; WEIGHT REDUCTION;

ADULT; ANTICONVULSANTS; CROSS-SECTIONAL STUDIES; DRUG THERAPY, COMBINATION; EPILEPSY; EUROPE; FEMALE; HUMANS; MALE; MIDDLE AGED; QUESTIONNAIRES;

EID: 79958291914     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/j.1600-0404.2010.01440.x     Document Type: Article

References (30)

1. World Health Organization, International Bureau for Epilepsy, International League Against Epilepsy. Global campaign against epilepsy: out of the shadows. 2003.
2. Mattson RH, Cramer JA, Collins JF et al. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic-clonic seizures. N Engl J Med 1985;313:145-51.
3. Baulac M. Rational conversion from antiepileptic polytherapy to monotherapy. Epileptic Disord 2003;5:125-32.
4. Langfitt J, Meador K. Want to improve epilepsy care?: ask the patient. Neurology 2004;62:6-7.
5. Cramer JA. Quality of life for people with epilepsy. Neurol Clin 1994;12:1-13.
6. Cramer JA. Quality of life assessment in clinical practice. Neurology 1999;53(5 Suppl 2):S49-52.
7. Cramer JA, Brandenburg NA, Xu X, Vera-Llonch M, Oster G. The impact of seizures and adverse effects on global health ratings. Epilepsy Behav 2007;11:179-84.
8. Gilliam FG, Fessler AJ, Baker G, Vahle V, Carter J, Attarian H. Systematic screening allows reduction of adverse antiepileptic drug effects: a randomized trial. Neurology 2004;62:23-7.
9. Uijl SG, Uiterwaal CS, Aldenkamp AP et al. A cross-sectional study of subjective complaints in patients with epilepsy who seem to be well-controlled with anti-epileptic drugs. Seizure 2006;15:242-8.
10. Mattson RH, Cramer JA, Collins JF. A comparison of valproate with carbamazepine for the treatment of complex partial seizures and secondarily generalized tonic-clonic seizures in adults. The Department of Veterans Affairs Epilepsy Cooperative Study No. 264 Group. N Engl J Med 1992;327:765-71.
11. Carpay JA, Aldenkamp AP, Van Donselaar CA. Complaints associated with the use of antiepileptic drugs: results from a community-based study. Seizure 2005;14:198-206.
12. Carreño M, Gil-Nagel A, Sánchez JC et al. Strategies to detect adverse effects of antiepileptic drugs in clinical practice. Epilepsy Behav 2008;13:178-83.
13. Tomson T. Drug selection for the newly diagnosed patient: when is a new generation antiepileptic drug indicated? J Neurol 2004;251:1043-9.
14. LaRoche SM, Helmers SL. The new antiepileptic drugs: scientific review. JAMA 2004;291:605-14.
15. Cramer JA, Fisher R, Ben-Menachem E, French J, Mattson RH. New antiepileptic drugs: comparison of key clinical trials. Epilepsia 1999;40:590-600.
16. Cramer JA, Ben Menachem E, French J. Review of treatment options for refractory epilepsy: new medications and vagal nerve stimulation. Epilepsy Res 2001;47:17-25.
17. Malphrus AD, Wilfong AA. Use of the newer antiepileptic drugs in pediatric epilepsies. Curr Treat Options Neurol 2007;9:256-67.
18. Kanner AM, Balabanov AJ. The use of monotherapy in patients with epilepsy: an appraisal of the new antiepileptic drugs. Curr Neurol Neurosci Rep 2005;5:322-8.
19. Perucca E, Meador KJ. Adverse effects of antiepileptic drugs. Acta Neurol Scand 2005;112:30-5.
20. Greenwood RS. Adverse effects of antiepileptic drugs. Epilepsia 2000;41(Suppl 2):S42-52.
21. Cramer JA, Smith DB, Mattson RH, Delgado Escueta AV, Collins JF. A method of quantification for the evaluation of antiepileptic drug therapy. Neurology 1983;33(3 Suppl 1):26-37.
22. Rowan AJ, Ramsay RE, Collins JF et al. New onset geriatric epilepsy: a randomized study of gabapentin, lamotrigine, and carbamazepine. Neurology 2005;64:1868-73.
23. Fisher RS, Vickrey BG, Gibson P et al. The impact of epilepsy from the patient's perspective II: views about therapy and health care. Epilepsy Res 2000;41:53-61.
24. Birbeck GL, Hays RD, Cui X, Vickrey BG. Seizure reduction and quality of life improvements in people with epilepsy. Epilepsia 2002;43:535-8.
25. Hessen E, Lossius MI, Gjerstad L. Antiepileptic monotherapy significantly impairs normative scores on common tests of executive functions. Acta Neurol Scand 2009;119:94-8.
26. Schreiner A, Stollhoff K, Ossig W et al. Conversion from valproic acid onto topiramate in adolescents and adults with epilepsy. Acta Neurol Scand 2009:119:304-12.
27. Zaccara G, Messori A, Cincotta M, Burchini G. Comparison of the efficacy and tolerability of new antiepileptic drugs: what can we learn from long-term studies? Acta Neurol Scand 2006;114:157-68.
28. Peltola J, Peltola M, Auvinen A, Raitanen J, Fallah M, Keränen T. Retention rates of new antiepileptic drugs in localization-related epilepsy: a single-center study. Acta Neurol Scand 2009;119:55-60.
29. Matsuura M. Patient satisfaction with polypharmacy reduction in chronic epileptics. Psychiatry Clin Neurosci 2000;54:249-53.
30. Cramer JA, Mattson RH, Prevey ML, Scheyer RD, Ouellette VL. How often is medication taken as prescribed? A novel assessment technique. JAMA 1989;261:3273-7.